1:22 PM
 | 
Nov 10, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Allergy Therapeutics begins Phase II trial of grass pollen allergy vaccine

Allergy Therapeutics plc (LSE:AGY) started the Phase II G205 trial of Pollinex Quattro Grass in about 440 patients with grass pollen allergy. The company told BioCentury it expects data in 2H18.

The double-blind, placebo-controlled, European trial will evaluate 4 different maximum doses, ranging from...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >